title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Methods | PMC10154324 | |||
Setting and procedure | vaginal infections, ’ | VAGINAL INFECTION | This prospective, randomized, observer-blinded single-center study was performed at the Medical University of Vienna, Department of Obstetrics and Gynecology, after approval by the ethics committee of the Medical University of Vienna (protocol nr.: 2258/2016) in accordance with the Declaration of Helsinki and Good Clin... | PMC10154324 |
Study groups | According to the Nugent scoring system, we differentiated between two patient groups: (1) IMLN4: pregnant women with an intermediate vaginal microbiota and a Nugent score of 4 | PMC10154324 | ||
Study endpoints | bleeding, vaginal or urinary tract infection, diarrhea, preterm premature rupture of the membranes and/or, constipation | SECONDARY, PRETERM LABOR, BLEEDING | The primary endpoint was restoration of the normal vaginal microbiota (Nugent score 0–3). The secondary endpoints were the incidence of PTD (defined as spontaneous birth at or before 36 + 6 gestational weeks) due to preterm premature rupture of the membranes and/or preterm labor, gestational age at delivery (recorded a... | PMC10154324 |
Acknowledgements | We thank Birgit Füssl, Germania Pharmazeutika, Vienna, Austria and Biose Pharmaceuticals (Arpajon-sur-Cère, France) for supplying the study medication. | PMC10154324 | ||
Author contributions | L.P. primary investigator, corresponding author, planed, organized and conducted study, wrote the main manuscript. AF. co-organized the study, co-wrote manuscript. I.R., N.J. recruited the patients, collection and saving of results. U.K., I.H. sample collection and recruited the patients. H.K. organization of the study... | PMC10154324 | ||
Data availability | Materials described in the manuscript, including all relevant raw data, will be freely available to any researcher wishing to use them for non-commercial purposes, without breaching participant confidentiality. Please contact coresponding author. | PMC10154324 | ||
Competing interests | The authors declare no competing interests. | PMC10154324 | ||
References | PMC10154324 | |||
Background and aims | NAFLD, PolandNon-alcoholic fatty liver | Edited by: Maria Rodriguez-Fernandez, Pontificia Universidad Católica de Chile, ChileReviewed by: Jingjie Zhao, Capital Medical University, China; Piotr Ossowski, Medical University of Silesia, PolandNon-alcoholic fatty liver disease(NAFLD) is common worldwide and has previously been reported to be associated with slee... | PMC10272397 | |
Methods | NAFLD, MR | We proposed a bidirectional Mendelian randomization (MR) analysis and performed validation analyses to dissect the association between NAFLD and sleep traits. Genetic instruments were used as proxies for NAFLD and sleep. Data of genome-wide association study(GWAS) were obtained from the center for neurogenomics and cog... | PMC10272397 | |
Results | NAFLD, Insomnia, Snoring | In total,7 traits associated with sleep and 4 traits associated with NAFLD are used in this study. A total of six results showed significant differences. Insomnia was associated with NAFLD (OR(95% CI)= 2.25(1.18,4.27), P = 0.01), Alanine transaminase levels (OR(95% CI)= 2.79(1.70, 4.56), P =4.71×10-5) and percent liver... | PMC10272397 | |
Conclusion | NAFLD, sleep traits, insomnia | SLEEP APNEA SYNDROME | Genetic evidence suggests putative causal relationships between NAFLD and a set of sleep traits, indicating that sleep traits deserves high priority in clinical practice. Not only the confirmed sleep apnea syndrome, but also the sleep duration and sleep state (such as insomnia) deserve clinical attention. Our study pro... | PMC10272397 |
Introduction | NAFLD, Sleep, liver injuries, MR, cirrhosis and hepatocellular carcinoma | CHRONIC LIVER DISEASE, LIVER FIBROSIS, HEPATIC STEATOSIS, NONALCOHOLIC FATTY LIVER DISEASE, DISEASES, STEATOHEPATITIS | Nonalcoholic fatty liver disease (NAFLD), one of the most common chronic liver disease in the world, affects 25% of the population worldwide and its prevalence is expected to increase further in the near future. NAFLD and its associated consequences have become one of the major public health problems due to changes in ... | PMC10272397 |
Methods | PMC10272397 | |||
Research design | NAFLD, napping, sleep-related traits, snoring, insomnia, impairment of liver function, steatosis | STEATOSIS | In this study, we see insomnia, daytime dozing, morningness, ease of getting up, sleep duration, daytime napping and snoring as sleep-related traits. Since the main traits of NAFLD are steatosis of the liver and impairment of liver function, we used the diagnosis of NAFLD, alanine transaminase levels, aspartate aminotr... | PMC10272397 |
Data sources | NAFLD, insomnia | NON-ALCOHOLIC FATTY LIVER DISEASE | The GWAS data for insomnia obtained from the Open GWAS database, a dataset published by Neale LABS in 2017 that included a sample of 336,082 participants from European populations. In addition to this, we also used six sleep parameters from the center for neurogenomics and cognitive research database (Details of the GW... | PMC10272397 |
Selection of instrumental variables | For the selection of IVs, a more relaxed threshold was used in order to include more SNPs, and SNPs that were significant for the whole genome (<5 × 10-7) were used as a selection to become IVs, which has been used in many other MR studies ( | PMC10272397 | ||
Statistical analysis | As assumed, three assumptions must be satisfied when using the MR method (1): the selected IVs must be strongly associated with the exposure (2); the selected IVs should not be associated with potential confounders (3); the selected IVs could only influence the outcomes through the exposure, but not other pathways We u... | PMC10272397 | ||
Results | NAFLD, sleep traits | NON-ALCOHOLIC FATTY LIVER DISEASE | We investigated the correlation of different sleep traits with NAFLD, with the IVW method providing the main results, while the results of the MR Egger and weighted median methods were also presented by us. Processes with P value < 0.05 for the IVW method and F value > 10 were considered as significant associations. We... | PMC10272397 |
Discussion | obesity, depression, mitochondrial dysfunction, sleep disorders, NAFLD.Although hepatic steatosis, hypoxia, inflammation, snoring, insomnia, sleep-related, sleep traits, liver damage, nonalcoholic steatohepatitis, hepatic steatosis, Insomnia, NAFLD, OSA, liver inflammation, MR, steatosis | OBESITY, CARDIOVASCULAR DISEASE, INSULIN RESISTANCE, OXIDATIVE STRESS, BREAST CANCER, HYPOXIA, INFLAMMATION, ALTERNATION, MITOCHONDRIAL DYSFUNCTION, DISEASES, PATHOGENESIS, POSITIVE, LIVER FIBROSIS, LIVER DAMAGE, NONALCOHOLIC STEATOHEPATITIS, HEPATIC STEATOSIS, TUMOR NECROSIS, DISEASE, HYPOXIC, STEATOSIS | Many previous reports have used MR studies to determine the causal relationship between sleep-related problems and various diseases and indicators, such as cardiovascular disease, breast cancer, depression and glycated hemoglobin (In the MR analysis of this paper, we systematically evaluated the causal relationship bet... | PMC10272397 |
Strength and limitations | NAFLD, anomalies, insomnia, MR, sleep traits | To our knowledge, this is the first bidirectional MR study that provides new insight into the causal associations between sleep traits and NAFLD. Our study has some strengths and limitations. The main advantage of this work is the use of bidirectional MR to explore the causal relationship between sleep traits and NAFLD... | PMC10272397 | |
Future research | NAFLD, sleep traits | We are thrilled to have found further evidence on the impact of different sleep traits on NAFLD, indicating that enhancing sleep is essential for the prevention and development of NAFLD. In the future, we may explore the specific mechanisms of sleep’s effects on NAFLD, including metabolic and inflammatory pathways, to ... | PMC10272397 | |
Conclusion | NAFLD | In summary, our findings suggest that sleep characteristics are associated with an elevated risk of NAFLD. Our study has significant implications for comprehending the causal relationship between sleep characteristics and NAFLD. Further research into their mechanisms and interactions is warranted. | PMC10272397 | |
Data availability statement | The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author. | PMC10272397 | ||
Author contributions | JJ | ZS, JJ and LZ conceived the study design. KW,YH and TX performed the statistical analysis. ZS wrote the manuscript and performed the data visualization. QW and FC supervised the study. All authors provided critical revisions of the draft and approved the submitted draft. | PMC10272397 | |
Acknowledgments | DISEASES | We sincerely acknowledge the contribution from the Open GWAS database, Neale lab, center for neurgenomics and cognitive research database, GWAS catalog database and all concerned investigators and consortiums for sharing the GWAS summary statistics on the diseases. | PMC10272397 | |
Conflict of interest | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. | PMC10272397 | ||
Publisher’s note | All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or ... | PMC10272397 | ||
References | PMC10272397 | |||
Methods | PMC10212647 | |||
Study design | Barrett | BARRETT |
Patients undergoing Barrett’s surveillance from the ACE-B trial
| PMC10212647 |
Participants |
Inclusion criteria were patients aged over 18 years with BE maximum circumferential length of ≥ 2 cm and/or maximum BE length of ≥ 3 cm (C2 and/or M3) diagnosed on pre-trial endoscopy (as per Prague Classification
| PMC10212647 | ||
Endoscopic procedure |
Patients received two endoscopy procedures during the trial period. In the standard arm, patients underwent HRWLE with diagnostic biopsies according to the gold standard (Seattle protocol). Briefly, the endoscopists were asked to perform a complete upper GI endoscopy with intubation to the second part of the duodenum,... | PMC10212647 | ||
Biopsy and histology |
Tissue biopsies were fixed in formalin and embedded in paraffin for histopathological assessment. Targeted and random biopsies were reviewed by a GI pathologist with extensive expertise in BE in accordance with the Vienna classification
| PMC10212647 | ||
Procedure time | The time taken to perform surveillance endoscopy was defined as the time interval between insertion of the endoscope to the time of patient extubation. | PMC10212647 | ||
Study outcomes | DDR, dysplasia | DYSPLASIA | Maximum BE lengths were classified into different strata: 2–5 cm, 6–10 cm, ≥ 11 cm. Time to perform endoscopy for each BE length strata was determined. To assess adherence to the Seattle protocol, the number of quadrantic biopsies taken per 2 cm length of BE was calculated by dividing total number of biopsies by half t... | PMC10212647 |
Statistical analysis | dysplasia | REGRESSION, DYSPLASIA |
Median, interquartile range (IQR), and range were calculated for endoscopy duration at different BE length strata. Mean and range were determined for number of quadrantic biopsies. Comparison of endoscopy duration and number of biopsies at different BE length strata were compared using a one-way analysis of variance.
... | PMC10212647 |
Results | MAY |
A total of 142 eligible patients completed the standard arm of the trial (HRWLE plus Seattle protocol biopsies) between May 2017 and October 2019. Baseline characteristics are shown in
| PMC10212647 | |
Patient demographics. | Barrett’s esophagus maximum length <, intramucosal carcinoma, dysplasia, LGD, Barrett, Barrett’s esophagus | BARRETT, DYSPLASIA | Age, mean (range), yearsMale sex, n (%)Maximum length, mean (range),Circumferential length of Barrett’s, mean (range)NDBEIndefinite for dysplasiaLGDHGD/IMCTotal number of tissue biopsies, nTargeted biopsies, n (%)Seattle protocol biopsies, n (%)Number of tissue biopsies per patient, mean (range)Targeted biopsies, mean ... | PMC10212647 |
Procedural time | Barrett’s esophagus |
The median time to perform HRWLE with Seattle protocol biopsies was 16.5 minutes (IQR 14.0–19.0 minutes). The time to perform BE surveillance endoscopy for increasing lengths of BE is shown in
Endoscopy duration and number of biopsies according to Barrett’s esophagus (BE) length. Median, interquartile range, maximum... | PMC10212647 | |
Adherence to the Seattle protocol |
To evaluate adherence to the Seattle protocol, the number of quadrantic biopsies taken per 2 cm of BE was assessed. The mean number of biopsies in the different strata 2–5 cm, 6–10 cm, and ≥ 11 cm was 4.3 (range 1.3–8.0), 3.8 (range 0.8–5.3), and 4.0 (range 3.4–4.3), respectively. Even though adherence to the Seattle ... | PMC10212647 | ||
Endoscopist experience | dysplasia | DYSPLASIA |
We evaluated whether endoscopist training grade influenced endoscopy performance. There was no difference in sensitivity for dysplasia detection from targeted (consultant 45.5 % vs. independent trainee 68.4 %;
| PMC10212647 |
Dysplasia detection rate | REGRESSION |
We then looked at the impact of endoscopy duration on DDR. Both DDR and endoscopy duration may be affected by BE length and endoscopist experience. Therefore, we performed multivariable logistic regression with endoscopy duration adjusting for BE length and endoscopist experience. As show in
| PMC10212647 | |
Multivariable logistic regression for detection of dysplasia obtained from targeted and Seattle protocol biopsies. | Barrett’s esophagus, dysplasia | REGRESSION, DYSPLASIA | OR, odds ratio.Adjusted OR for endoscopy duration, adjusted for endoscopist experience and Barrett’s esophagus maximum length from multivariable logistic regression.
Linear regression for dysplasia detection rate (DDR) and endoscopy duration per maximum Barrett’s esophagus (BE) length for all biopsies, targeted biopsi... | PMC10212647 |
Discussion | cancer, dysplasia, BE-related neoplasia | CANCER, DISEASE, DYSPLASIA | This study demonstrated that the median duration for an adequate BE endoscopic surveillance procedure was 16.5 minutes, no difference between consultant endoscopists and independent trainees who had completed specialist training. In addition, we found evidence that the duration of the endoscopy procedure correlated wit... | PMC10212647 |
Tables 1 s–4 s, Fig. 1 s
| Supplementary materialZusatzmaterial | PMC10212647 | ||
References | PMC10212647 | |||
Purpose | RCC | ADVANCED RENAL CELL CARCINOMA, RCC | In the phase 3 CheckMate 9ER trial, intravenous nivolumab (240 mg every 2 weeks) plus oral cabozantinib (40 mg/day) improved progression-free survival (PFS) versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC). To support cabozantinib dosing with the combination, this exposure–response analysi... | PMC9905187 |
Methods | ADVERSE EVENTS, CPH | Dose modification was allowed with cabozantinib (holds and reductions) to manage adverse events (AEs). The population pharmacokinetics analysis was updated and used to generate individual predicted cabozantinib exposure measures. Kaplan–Meier plots and time-to-event Cox proportional hazard (CPH) exposure–response model... | PMC9905187 | |
Results | palmar-plantar-erythrodysesthesia, diarrhea | CPH | Kaplan–Meier plots showed no clear difference in PFS across cabozantinib exposure quartiles. Cabozantinib exposure did not significantly affect the hazard of PFS in the CPH base model nor in the final model. In contrast, baseline albumin and nivolumab clearance had a significant effect on PFS. There was no significant ... | PMC9905187 |
Conclusion | RCC | RCC | To optimize individual cabozantinib exposure, these data support the dose modification strategies in CheckMate 9ER for cabozantinib in patients with advanced RCC when combined with nivolumab.
| PMC9905187 |
Supplementary Information | The online version contains supplementary material available at 10.1007/s00280-022-04500-9. | PMC9905187 | ||
Keywords | PMC9905187 | |||
Introduction | renal cell carcinoma, death, genitourinary malignancies, RCC | RENAL CELL CARCINOMA, RCC | Over the last decade, improved understanding of the angiogenic and immunogenic biology of renal cell carcinoma (RCC) has led to development of tyrosine kinase inhibitors (TKI) that target the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors that target the programmed cell death 1 (PD... | PMC9905187 |
Materials and methods | PMC9905187 | |||
Study design and data | RCC | BLOOD, RCC | The exposure–response analyses were conducted using data from the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced RCC. CheckMate 9ER was an open-label, randomized phase 3 trial of nivolumab (240 mg intravenously every 2 weeks) plus cabozantinib (40 mg orally QD) versus... | PMC9905187 |
Population pharmacokinetic model | MALIGNANCIES | The PopPK analysis included plasma cabozantinib concentration–time data from CheckMate 9ER and 10 studies from a previously developed integrated PopPK model that characterized cabozantinib concentration data from healthy subjects and patients with various types of malignancies [The analytical data preparation has been ... | PMC9905187 | |
Exposure–response analysis for time-to-event endpoints | PMC9905187 | |||
Efficacy and safety endpoints | fatigue/asthenia, death, hypertension, diarrhea | PALMAR-PLANTAR ERYTHRODYSESTHESIA, EVENTS, HYPERTENSION | Time-to-event analyses were performed to characterize the exposure–response relationship between cabozantinib exposure and PFS (defined as the time from randomization to radiographic progression per RECIST v1.1 by BICR, or death), cabozantinib dose modification, and each of the following AEs commonly associated with ca... | PMC9905187 |
Dataset construction and preliminary analyses | EVENT | Individual average cabozantinib concentrations from time zero to the event or censoring time (CAVG0T) were calculated from the estimated individual PK parameters of the final PopPK model and individual dosing history; CAVG0T was used for the exposure–response analysis dataset to link clinical endpoints with individual ... | PMC9905187 | |
Cox proportional hazards (CPH) model | CPH | CPH models were used to describe the relative hazard for each of the clinical efficacy and safety endpoints.The general form of the CPH model is represented by the equation (Eq. | PMC9905187 | |
Model development | CPH | Separate CPH models were developed for each of the clinical endpoints using data from the CheckMate 9ER trial. The impact of cabozantinib exposure on relative hazard was evaluated during base model development. A drop in − 2 log likelihood (− 2LL) when including cabozantinib exposure in the CPH model was considered sig... | PMC9905187 | |
Covariate analysis | tumor, RCC | DISEASE, LIVER METASTASIS, TUMOR, RCC | Covariate effects were assessed for the PFS model. Covariates were added to the base model simultaneously to form a full model followed by stepwise backward elimination to identify the most parsimonious model. Statistical significance of covariate-parameter relationships was assessed with the Wald test, at Covariates e... | PMC9905187 |
Final model evaluation and simulations | CPH | The predictive performance of the PopPK model and time-to-event models was evaluated using visual predictive checks (VPC). Simulations were also performed using the final CPH model parameter estimates to predict the incidence of efficacy and safety endpoints for different dose levels. | PMC9905187 | |
Software | REGRESSION | For PopPK modeling, analyses were performed using nonlinear mixed effects modeling methodology as implemented in the NONMEM software system, version 7.3 (ICON Development Solutions, Ellicott City, MD). For exposure–response analysis, time-to-event analyses were performed using the Cox proportional hazards regression (P... | PMC9905187 | |
Results | PMC9905187 | |||
Exposure–response analyses | EVENTS, EVENT, CPH | For exposure–response analyses of PFS and safety endpoints, the number of patients in the CheckMate 9ER trial with events and the total number at risk are listed in Supplementary Table S3. These patients received at least one dose of nivolumab plus cabozantinib and had a baseline and/or at least one post-baseline asses... | PMC9905187 | |
Progression-free survival | death | CPH, EVENT, DISEASE PROGRESSION | Figure Kaplan–Meier plot for progression-free survival by average exposure quartiles. Shaded regions represent 95% confidence intervals for each exposure quartile (Q#) of CAVG0T, the predicted average cabozantinib concentration from time zero to the event or censoringA linear CPH model including all 311 patients was us... | PMC9905187 |
Covariate effects for PFS | EVENT | Table Covariate effects in the final model of progression-free survival model. Reference is a male patient with nivolumab clearance of 0.009 L/h, baseline albumin of 41 g/L, and CAVG0T, the predicted average cabozantinib concentration from time zero to the event or censoring, of 558 ng/mL. Continuous covariates are tes... | PMC9905187 | |
Safety endpoints | PMC9905187 | |||
Dose modifications | Among patients who received nivolumab plus cabozantinib, 318 were included in the analysis to characterize the relationship between individual predicted cabozantinib CL/F and the rate of dose modifications (Supplementary Table S3); 285 had a dose modification. The exploratory KM plot for cabozantinib dose modification ... | PMC9905187 | ||
Adverse events | diarrhea | PALMAR-PLANTAR ERYTHRODYSESTHESIA | Among the AE endpoints evaluated, exploratory KM plots by exposure quartile indicated an association of cabozantinib exposure with PPE (Grade ≥ 1) and diarrhea (Grade ≥ 3) but not with the other AE endpoints. The exploratory KM plots for PPE (Fig. Kaplan–Meier Plot for Grade ≥ 1 palmar-plantar erythrodysesthesia ( | PMC9905187 |
Discussion | NSCLC, death, melanoma, diarrhea, rash, fatigue/asthenia, RCC, hypertension | NON-SMALL CELL LUNG CANCER, DISEASE PROGRESSION, MELANOMA, ADVERSE EVENTS, DISEASE, CPH, NSCLC, HYPOTHYROIDISM, HYPERTENSION, RCC | The CheckMate 9ER trial investigated the efficacy and safety of nivolumab in combination with cabozantinib compared with sunitinib in patients with previously untreated advanced RCC [Nivolumab plus cabozantinib significantly improved the primary efficacy endpoint of PFS compared with sunitinib [In patients receiving th... | PMC9905187 |
Acknowledgements | We thank the patients, their families, the investigators, and site staff. We thank Sravan Karumanchi (Ann Arbor Pharmacometrics Group) for providing support for the analyses and Linh Nguyen (Exelixis, Inc.) for her contributions to initial planning for the analyses. Writing and editorial assistance was provided by Ange... | PMC9905187 | ||
Author contributions | All authors analyzed and interpreted the data and provided critical review of the manuscript. BDT, JL, and RF drafted the manuscript. All authors approved the final version of the manuscript for submission and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or inte... | PMC9905187 | ||
Funding | The CheckMate 9ER study was funded by Bristol Myers Squibb in collaboration with Ono Pharmaceutical and with Exelixis, Ipsen Pharma, and Takeda Pharmaceutical. The analysis reported here was funded by Exelixis, Inc. (Alameda, CA, USA). | PMC9905187 | ||
Data availability | Inquiries can be directed to the corresponding author. | PMC9905187 | ||
Code availability | Inquiries can be directed to the corresponding author. | PMC9905187 | ||
Declarations | PMC9905187 | |||
Conflict of interest | All authors are employees and stockholders of Exelixis, Inc. | PMC9905187 | ||
Ethical approval | The studies included in the analysis were conducted in accordance with the Declaration of Helsinki and the good clinical practice guidelines and were approved by the institutional review board or ethics committee at each center. | PMC9905187 | ||
Consent to participate | All patients provided written informed consent | PMC9905187 | ||
Consent to publish | Not applicable. | PMC9905187 | ||
References | PMC9905187 | |||
1. Introduction | obesity, metabolic complications, Alzheimer’s disease, vascular disease | OBESITY, OXIDATIVE STRESS, VASCULAR DISEASE, METABOLIC DISORDERS | This study aimed to investigate the effects of Brazilian propolis on body fat mass and levels of adiponectin and reactive oxygen species among community-dwelling elderly females. This was a double-blind randomized placebo-controlled trial. Altogether, 78 females aged 66–84 years were randomly assigned to the propolis (... | PMC9861743 |
2. Materials and Methods | PMC9861743 | |||
2.1. Participants | psychiatric, dementia | DISEASES, DISORDERS | Healthy postmenopausal elderly females were recruited as trial volunteers for this study via the use of a public relations magazine in Mihara City, Japan. The inclusion criteria were healthy, postmenopausal females aged 65 years or older who were independent in their daily lives. Meanwhile, the exclusion criteria were ... | PMC9861743 |
2.2. Study Design | This was a randomized, double-blind, and placebo-controlled trial. The PRO group were given three soft capsules containing 227 mg/3 capsules of propolis twice per day, i.e., after breakfast and dinner (total intake: 454 mg/6 capsules/day) for 12 weeks. Meanwhile, the PLA group were given placebo capsules at the same do... | PMC9861743 | ||
2.3. Brazilian Propolis Supplementation | We prepared 227 mg/3 capsules of propolis supplement using Propolis 300 | PMC9861743 | ||
2.4. Assessment Procedures | dehydration, hand dynamometer, dual-energy X-ray absorptiometry | DEHYDRATION, OXIDATIVE STRESS | All assessments were performed by a physician, radiologist, nurse, dietitian, and ten physical therapists. The assessments before and after the intervention lasted for approximately 60 min. They were conducted at the Mihara Campus of Prefectural University of Hiroshima using a standardized protocol by the same research... | PMC9861743 |
2.5. Statistical Analysis | All continuous data were presented as mean standard error of the mean or median (interquartile range) for parametric or nonparametric continuous variables, respectively. The baseline characteristics between the two groups were compared using a Student’s unpaired The sample size calculation and power analysis were perfo... | PMC9861743 | ||
4. Discussion | vascular disorders | OBESE, OXIDATIVE STRESS, DISORDERS, VASCULAR DISORDERS, INSULIN RESISTANCE, POSTMENOPAUSAL SYMPTOMS, TYPE 2 DIABETES, DISEASES | Our prospective interventional study showed that propolis had a positive effect on absolute and relative fat mass, relative lean body mass, and levels of adiponectin and ROS among community-dwelling elderly females. Therefore, propolis supplementation may be an effective strategy for preventing disorders caused by body... | PMC9861743 |
Author Contributions | N.M. | Conceptualization, M.K. and H.F.; methodology, M.K., R.N. and H.F.; software, T.I., N.T., M.T. and T.N.; validation, T.H. and H.F.; formal analysis, M.K., T.I., R.N., M.T. and T.N.; investigation, M.K., T.I., R.N., M.T., H.I., N.T., N.M., H.K. and T.H.; resources, M.K., T.I., H.K., T.H. and H.F.; data curation, R.N., N... | PMC9861743 | |
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Prefectural University of Hiroshima (15MH064) and Kobe University Graduate School of Health Sciences (277-2). Furthermore, the trial was registered at the University Hospita... | PMC9861743 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC9861743 | ||
Data Availability Statement | The data that support the findings of this study are available from the corresponding author upon reasonable request. | PMC9861743 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC9861743 | ||
References | toxicity | HIVES | CONSORT flowchart. PLA, placebo; PRO, propolis; ITT, intention-to-treat; PP, per-protocol. Obtained from honeybee hives and extracted using ethanol. Wheat germ oil is extracted by pressing the wheat germ and is used as a solvent for propolis supplements. Therefore, it was selected as a placebo in this study. The supple... | PMC9861743 |
1. Introduction | stress-related injuries, post-traumatic, ’ post-traumatic, fatigue | SECONDARY, STS | This randomized controlled trial examined the impact of a psychoeducational group program on the mental well-being of unit-based nurse leaders, specifically nurse managers and assistant nurse managers. The program was developed around the themes of resilience, insight, self-compassion, and empowerment to fight burnout ... | PMC10252280 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.